Abeona Therapeutics Inc. (Nasdaq: ABEO) is a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare genetic diseases
Developing therapies for rare disease requires new approaches and strong collaboration between researchers, industry, regulators and patient groups.
Abeona was forged from the company’s close collaborations with key stakeholders all dedicated to transforming new biotechnology insights into breakthrough treatments for rare diseases.
Developing therapies for rare disease requires new approaches and strong collaboration between researchers, industry, regulators and patient groups.
Abeona was forged from the company’s close collaborations with key stakeholders all dedicated to transforming new biotechnology insights into breakthrough treatments for rare diseases.
Location: United States, Ohio, Cleveland
Employees: 51-200
Total raised: $12.1M
Founded date: 2015
Investors 1
| Date | Name | Website |
| - | Elysia Cap... | elysiacapi... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 28.07.2015 | - | $8.5M | - |
| 01.12.2014 | - | $3.6M | - |
Mentions in press and media 10
| Date | Title | Description |
| 03.05.2024 | Abeona Therapeutics Announces Pricing of $75 Million Underwritten Offering of Common Stock and Pre-Funded Warrants | - |
| 05.03.2024 | Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | - |
| 08.01.2024 | Abeona Therapeutics Announces $50 Million Credit Facility | - |
| 08.01.2024 | Abeona Therapeutics Announces $50 Million Credit Facility | CLEVELAND, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that it has entered into a $50 million credit facility with the Avenue Venture Opportunities Fund, L.P. The credit agreement, which has a t... |
| 03.11.2022 | Abeona Therapeutics Announces $35 Million Private Placement Financing | - |
| 28.07.2015 | Abeona Therapeutics using CRISPR to treat Fanconi anemia, raises $8.5M | Right now, the only quasi-effective treatment for Fanconi anemia is bone marrow transplant. Abeona researchers are developing a protein-RNA complex made up on the Cas9 enzyme to recognize the faulty DNA sequence, then guide further genetic ... |
| 01.12.2014 | Abeona Therapeutics Closes $3.6M Funding Round | Abeona Therapeutics, a Cleveland-based biotechnology startup, closed a $3.6m funding round. Investors include U.S.-based Cure Sanfilippo Foundation, Sanfilippo Research Foundation (SRF), Team Sanfilippo, the Abby Grace Foundation, and the N... |
| 08.11.2014 | Funding roundup: Using lasers to change eye color from brown to blue, and more. | Biotech Abeona Therapeutics – Cleveland, Ohio $3.6 million in equity raised of a proposed $5 million round Developing treatments for orphan childhood lysosomal storage disease. Its lead candidates, ABX-A and ABX-B, treat Sanfilippo Type A a... |
| - | Abeona Therapeutics using CRISPR to treat Fanconi anemia, raises $8.5M | New York startup Abeona Therapeutics just raised $8.5 million to expand its gene therapy pipeline for rare disease like Sanfilippo syndrome, juvenile Batten disease and Fanconi anemia. Notably, the company’s using CRISPR/Cas9-based techniqu... |
| - | Funding roundup: Using lasers to change eye color from brown to blue, and more. | Each week, many millions are invested into life sciences startups. For example, Stroma Medical – a laser therapy company that claims it can swap your eye color from brown to blue – is in the midst of clinical trials and has raised more cash... |